|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Alnylam Pharmaceuticals (ALNY) Receives Allowance from European Patent Office for Tuschl II Patent, Exclusively Licensed from Max Planck Society
8/1/2007 11:04:29 AM
CAMBRIDGE, Mass. & MUNICH, Germany--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that a key fundamental patent from its exclusively held “Tuschl II” patent estate has received Rule 51(4) EPC notification from the European Patent Office (EPO); this notification is equivalent to a “Notice of Allowance” by the United States Patent and Trademark Office. It is expected that the patent will be granted by the EPO within the next six months. The European patent (EP 1407044 or “’044 Patent”) broadly covers compositions, methods, and uses of small interfering RNAs (siRNAs), the molecules that mediate RNAi. Alnylam also announced today that the Tuschl II patent has been granted in Australia (AU2002235744). The Tuschl II patent family is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Max Planck Innovation GmbH, the licensing agent for the Max Planck Society.
|
|
|
|
|
|
|
|
|
|
|